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ABSTRACT 
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Correspondence to: Dr. Pather M. e-mail: mpather@sun.ac.za 
 
Background 
 
Adherence to HAART is key to any successful HAART programme. In Madzikane KaZulu Memorial 
Hospital ARV Clinic, there is an increasing number of patients on HAART and an increasing number of 
patients still awaiting HAART initiation. With the paucity of healthcare personnel in this rural district 
hospital, suboptimal patient’s preparation for HAART often occurs, and the HAART defaulter rate is on 
the increase. This is may be attributed to an interplay of factors affecting HAART adherence. 
 
Aim and Objectives 
 
The aim of this research was to determine the prevalence of established factors associated with adherence 
to Highly Active Antiretroviral Therapy (HAART) in non-adhering patients at the Madzikane KaZulu 
Memorial Hospital (MKMH) ARV clinic. 
 
The objectives were: 
 To conduct an audit on all case files of patients on HAART over the study period. 
 To explore the behavioural aspects of poor HAART adherence in a focused group discussion. 
 To describe the factors associated with good HAART adherence 
 
Methods 
 
Study design: A cross-sectional descriptive study which focused on determining the prevalence of 
established factors( patient-related, therapy-related and facility-related factors) affecting HAART 
adherence at the ARV clinic was carried out among identified HAART non-adhering patients. Patients 
that were not adhering with HAART between the period of January 2009 and December 2010 were 
selected for the study. These patients were 19 years or more and had been on HAART for at least two 
months. The study was carried out between November and December 2010. The result of the focused 
group discussion was utilized to refine the development of the questionnaire. 
 
Setting: The study was conducted at the Madzikane KaZulu Memorial Hospital ARV clinic. This is a 
modern 269 bed district hospital in the Mount Frere, Alfred Nzo district, Eastern Cape Province of South 
Africa. This is a predominantly rural region. 
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Results:  
 
Data for analysis was provided by 215 patients that fulfilled the inclusion criteria. The prevalence rate of 
the factors affecting HAART adherence at the hospitals ARV clinic was 24%. A total of 60% of the 
patients were females. Majority of the patients (86.1%) had treatment supporters, and more than half of 
the patients (57.2%) were unemployed and not on disability grant. A total of 62.8% of the patients prefer 
to take their ARV at a clinic near them, and the majority of these patients (96.3%) want to start taking 
their ARV in a nearby clinic within 6months. The female gender, unemployment not on disability grant, 
longer period on HAART, Regimen 1A ARV( stavudine or tenofovir plus lamivudine and efavirenz 
according to the National ART guideline 2004 and its modified version of April 2010) single marital 
status and probably poorly selected unprepared treatment supporters, are associated with poor HAART 
adherence at this ARV clinic. 
 
Conclusion 
 
The study revealed that the prevalence rate of the factors affecting HAART adherence at the Madzikane 
KaZulu Hospital ARV clinic was 24% amongst HAART non-adhering patients. These patients had the 
prevalence rate of patient-related factors (12.4%)  more than double of the prevalence rates of therapy 
related factors (5.8%), and facility related factors (5.7%). Topmost amongst the associated factors for not 
adhering to HAART were: not belonging to a support group, the pills making the patient feel unwell, and 
the ARV clinic being too far from where the patients live. Efforts should be targeted at enrolling the 
patients in support groups, encouraging the use of HAART regimens that have good tolerability profiles, 
and establishing the down referral. 
 
 
 
 
List of abbreviations 
 
ARV: Antiretroviral 
 
HAART: Highly active antiretroviral therapy 
 
ART: Antiretroviral therapy 
 
HIV: Human immunodeficiency virus 
 
PHC: Primary health care. 
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INTRODUCTION 
 
The problem inspiring the research question stems from the context of an increasing defaulter rate, 
increasing number of clients on HAART and increasing number awaiting initiation on HAART, same 
number of staff at the ARV clinic and the down referral system which is yet to commence. The researcher 
was personally motivated and committed to do this research because of the need to improve adherence 
and potentially decreasing the defaulter rate, the work load on the ARV clinic staff and by contributing 
towards kick-starting the down referral system which is long overdue. The down referral is a systematic  
process of routinely transferring patients who have been on HAART at a higher level health facility to a 
lower level health facility for continuity of care. The motivation for doing the study was based on the long 
queue of patients at the ARV clinic every working day, which leaves the ARV clinic staff that is few in 
number with an enormous job of attending to these patients. There is also an ever-increasing call to attend 
to these patients holistically at every clinic visit, which is not always practically possible given the 
constraints in available staff. 
 
Quality of patients care is likely to be compromised. Previous studies on this topic were carried out in 
Khayelitsha, a township in Cape Town, and Soweto which is a big residential area near Johannesburg. 
These areas have widespread poverty, unemployment and HIV/AIDS similar to that of Mount Frere 
where the researcher conducted the study. However these areas have some influence from the big cities 
near them in terms of social amenities, job opportunities and level of development in general, which are 
way too different from what is obtainable in the Mount Frere community, a deeply rural community in the 
Alfred Nzo District of the Eastern Cape Province. All these set a stage for differences in adherence to 
HAART by patients in Mount Frere when compared to patients in Khayelitsha and Soweto.  
 
The researcher hoped that the study will impact positively on adherence improvement (and overtly 
improving the ARV clinic performance), engaging other stakeholders in the HIV/AIDS management at 
the Clinic and Community and providing inputs towards kick-starting the down referral system. Literature 
review revealed  that there are broadly three factors affecting HAART adherence (Therapy Regimen 
Related Factors, Patient Related Factors and Facility Related Factors).
1-6
 Adherence is however measured 
with many tools though none of them is perfect. Adherence is highly unpredictable when considering 
clients’ biophysical profile and a well focused multidisciplinary individualized strategy is paramount in 
solving adherence related issues. Near perfect Adherence ultimately is of fundamental importance for any 
successful HAART programme.
1
 The long term HAART goals include suppression of viraemia and 
reduction of risk of resistance emergence, restoration and preservation of immune function, reduction of 
HIV-related morbidity and mortality, and lifestyle adjustment.
7
 
 
 
LITERATURE REVIEW 
 
The UNAIDS report of 2009 reveals that sub-Saharan Africa accounts for 71% of all new HIV infections 
in 2008 , and a total of 5.7 million South Africans are infected.
8
 However with the need to scale up 
comprehensive treatment interventions by the government in partnership with various stakeholders, this 
HIV/AIDS scourge in the country is receiving much long overdue attention presently than was the case 
some years back. Increasing access to HAART has been shown to alter the trend of morbidity and 
mortality attributable to HIV/AIDS over time in any given place.
9-11
 
 
More and more studies on adherence issues in Highly Active Antiretroviral Therapy (HAART) 
programmes keep coming up thereby underscoring the importance of adherence. Adherence has been 
shown to be a cornerstone for any successful antiretroviral therapy, with low adherence being one of  the 
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leading causes of therapeutic failure.
4 
Adherence has been defined in practical terms as the extent to 
which a person’s behaviour in  taking medications, following dietary specifications and/or executing 
lifestyle changes correspond to agreed recommendations from a health care provider.
12
 Adherence has 
also been defined in terms of clinic attendance, deficits in the number of pills given and the number 
consumed. These can be measured by using tools like physicians’ assessment, self-report questionnaires, 
pharmacy records, pill counts, antiretroviral clinic attendance register and electronic drug monitors. 
However, these tools used in adherence measurement have biases inherent in them.
13
 These biases 
include: subjectivity and inaccuracy in physician’s assessment, accuracy affected by poor patients recall; 
mistimed doses; inability to determine who took the pills in patients self-report, pill count and pharmacy 
refill records, in addition to the expensive device used in electronic drug monitoring which does not 
indicate who consumed the pills or whether the pill was consumed or not.
13
  
 
The qualitative aspect of adherence like treatment timing, food restrictions, correct dosage intake cannot 
be objectively measured by all these tools thereby leaving us with no gold standard tool designed to 
measure adherence.
14
 Studies have also shown that patient self-reported adherence is known to be overly 
optimistic 
15,16
 because of recall bias or desire to please the provider and prevent criticism, or both.
6
 
A good number of factors have been shown to influence adherence. These include therapy regimen 
related factors, patients related factors and facility related factors.
1
 Wagner reported better adherence in 
patients living alone,
5
 which contrasts to the pattern of adherence more likely to be obtained in resource 
poor settings like the research study location. With the increasing prevalence of weakened family 
ties/structures and child headed families in sub-Saharan Africa especially in Southern Africa, the social 
climate will keep playing a significant role in determining adherence patterns of patients on HAART. 
 
A cross sectional study to evaluate factors associated with adherence to antiretroviral therapy by Brazilian 
HIV-infected patients showed that the most frequently cited reason for non-adherence was ‘being away 
from home’.17 This has also been reported in studies conducted in Soweto South Africa and in the United 
States.
18,19
 Antiretroviral therapy dosing interval, food restrictions, therapy side effects, life style 
modification, stigmatization, lack of social support and poor  patient-provider relationship are amongst 
other obstacles to HAART adherence that have been reported. Studies however showed that adherence 
pattern of an individual cannot be predicted based on demographic profiling.
20,21
 
 
With the current challenges faced in developing countries whereby the need to improve on the HAART 
coverage and not compromising the quality of the programme,
21,22
 adherence promotion strategies need 
strengthening. Studies have shown that high adherence rates have been achieved in sub-Saharan Africa as 
evidenced in >95% adherence rate in 88% of patients in a Soweto South Africa study
18 
and median 
adherence rate of 93.5%  reported in Cape Town South Africa.
20
  
 
The researcher hopes that this study will further identify the already established factors affecting 
adherence to HAART in the ARV clinic of Madzikane KaZulu Memorial Hospital, which is a district 
hospital in a deeply rural setting. This will invariably lend support to the fact that these factors are well 
established in affecting HAART adherence in various settings. Furthermore, the researcher aims to 
provide information on the adherence pattern to HAART in a rural setting in South Africa taking 
cognizance of the impact of the social environment on HAART adherence in this setting that will be 
different from reports obtained in semi-urban and urban settings in South Africa. 
 
However the issue still remains on how these high adherence rates can be sustained over time in order to 
achieve the long term HAART goals. In a study conducted in Senegal, over 95% of patients on HAART 
had >80% adherence after one month on therapy but 18 months later only 80% remained above that 
level.
23
 This invariably implies that adherence should be a continuous process and any contact with the 
patient will be an avenue to address adherence issues. Some of the methods which help in improving 
adherence include; provision of adherence promoting devices( pill boxes, alarms/beepers, diaries),
20,24,25
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reinforcing the roles of treatment supporters for each patient on HAART which also includes the 
proposed DOT(directly observed therapy) HAART model,
26,27
 simplifying therapy regimen,
28
 enrolling 
patients on HAART in treatment support groups, and prompt treatment of side effects of HAART. All 
these methods will not yield the needed results if the patient lacks the understanding of the HAART 
objectives and goals. Therefore continuous patient education and motivation on the treatment goals of 
HAART is necessary in achieving and sustaining high adherence level.
7
 Adherence issues should as much 
as possible be individualized and appropriate adherence-enhancing intervention undertaken for each 
patient as varying reasons for poor adherence to HAART differ from one patient to another.
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The researcher hopes that this study will impact positively in promoting the adherence enhancing 
structures already in place at the ARV clinic which include; treatment supporter for each patient on 
HAART,
29
 completion of at least 3 sessions of Pre-ART assessment prior to initiation of HAART and use 
of support groups amongst others. In addition, soliciting partnership between the non governmental 
organizations/ community based organizations/ faith based organizations and the ARV clinic and 
fostering the mentorship from the regional training centre of the Walter Sisulu University with the ARV 
clinic, will surely go a long way in impacting positively on adherence levels in the clinic. These bodies 
will also provide logistics in terms of capacity building, human resources provision/training and 
continuous development, and provision of other material resources that are crucial in the HAART 
programme. The sustainability of optimum adherence especially in sub-Sahara Africa, calls for further 
qualitative research into the behavioural reasons for non adherence to HAART.
13
 More attention, 
therefore, should be focused on adherence studies as it forms the cornerstone of any successful therapy. 
Research towards developing a convenient tool to monitor adherence by clinicians in ARV programmes is 
very crucial.
30 
 HAART effectiveness can be improved by putting on greater efforts to design and evaluate 
interventions aimed at enhancing adherence. This has necessitated a study on the prevalence of 
established factors affecting HAART adherence at the Madzikane KaZulu Memorial Hospital’s ARV 
clinic. 
 
AIM 
 
The aim of this research was to determine the prevalence of established factors affecting adherence to 
Highly Active Antiretroviral Therapy (HAART) in non-adhering patients at the Madzikane KaZulu 
Memorial Hospital (MKMH) ARV clinic. 
 
The objectives were: 
 To conduct an audit on all case files of patients on HAART over the study period. 
 To explore the behavioural aspects of poor HAART adherence in a focused group discussion. 
 To describe the factors associated with good HAART adherence 
 
METHODS 
 
A cross-sectional descriptive study which focused on determining the prevalence of established factors 
affecting HAART adherence at the ARV clinic was carried out among identified HAART non adhering 
patients. HAART non adhering patients are those that either had unbalanced pill counts for two or more 
months or missed ARV clinic appointment days for ARV refill for two or more months, or both. HAART 
non adhering patients between the period of January 2009 and December 2010 were selected for the 
study. The inclusion criteria are; adult patients who are 19 years and above, who have been on HAART 
for at least 2 months within January 2009 and December 2010. Exclusion criteria are; patients with 
cognitive impairment and transfer-out patients to other facilities Approval for the study was obtained 
from the Ethics Committee of University of Stellenbosch with reference number N10/02/034, and the 
Eastern Cape Department of Health. The study was carried out between November 2010 and December 
2010. 
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Setting 
 
Madzikane KaZulu Memorial Hospital is a newly built rural district hospital in the Mount Frere 
community of the Eastern Cape Province. The hospital was built under the national hospitals 
revitalization project with modern state of the art facilities. The ARV clinic in the hospital caters for more 
than one thousand patients, with approximately ten healthcare workers( 2 doctors, 3 nurses, 1pharmacist, 
1 social worker, 3 vlay councilors) and four feeder clinics( PHC clinics that prepare patients for HAART 
and refer them to the hospitals’ ARV clinic for HAART initiation and management). These feeder clinics 
are; Mtwana clinic, Mpoza clinic, Tshungwana clinic and Gate way clinic. 
 
Study Population/Sampling Procedure 
 
The Stellenbosch University centre for Statistical Consultation assisted in calculating the sample size for 
the study, which was 263 within a confidence interval of 95% with a precision of 6%. Eligible patients 
were randomly selected from the ARV Clinic attendance records and pharmacy records. A simple random 
sample was taken. The research ethics committees of both the Stellenbosch University and Eastern Cape 
Department of Health approved this study. Permission was obtained from the Chief Executive Officer of 
the Madzikane KaZulu Memorial Hospital as well as from the hospital’s ARV clinic co-ordinator. 
 
Pilot Study/Data Collection Method 
 
A semi-structured interviewer administered questionnaire was the main tool utilized in this study. The 
three paged questionnaire was designed to cover demographic variables, patient related factors, therapy 
related factors, facility related factors, of adherence, and down referral data. 
 
An audit was conducted on the case files of the patients attending the ARV clinic, and defaulters that 
fulfilled the inclusion criteria identified.  A total of 217 patients had unbalanced pill counts for two 
months or more, while 68 patients missed ARV clinic attendance for two months or more. A total of 32 
patients had unbalanced pill count and missed ARV clinic attendance for  two months or more. A pilot 
survey was carried out with five randomly selected HAART defaulters and colleagues at work. Their 
feedback revealed that the semi-structured questionnaire was unambiguous, with simple questions and 
response options. 
 
A focus group discussion was also conducted with seven identified HAART non adhering patients, with 
the help of an interpreter. The discussion was analysed afterwards and three themes developed. These 
were; reminders versus preventers of HAART consumption, life style adjustment issues, and down 
referral issues. These themes were covered in the three paged semi-structured questionnaire. The result of 
the focused group discussion was utilized in further refining the semi-structured questionnaire. 
 
Two lay counselors, one from the ARV clinic and the other a volunteer, were trained on the 
administration of the questionnaire. A total of 280 questionnaires were administered to identified HAART 
non adhering patients at the ARV clinic on their clinic appointment days. The questions were translated to 
Isixhosa to the patients by the trained lay counselors whenever the need arose. Participation in the study 
was strictly on voluntary basis. Informed consent was obtained from all participants and all had the 
information leaflet verbally explained to them in their local language Isixhosa when needed. 
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Data Analysis 
 
Of the 280 questionnaires administered to the patients, 215 qualified for analysis. The remaining 65 
questionnaires were not valid for analysis due to the following reasons: 
 
1. 47 questionnaires were incomplete. 
2. 14 patients had been on HAART for less than 2 months. 
3. 4 patients were below 19 years of age. 
Microsoft office Excel spread sheet 2007 version was used to capture the data. The components of the 
data were each analysed separately and the results arranged in figures. 
 
Ethical Considerations 
 
 The following ethical considerations have been considered in this research: 
 
Informed consent was obtained from all the participants prior to taking part in the study. 
Confidentiality was strictly maintained throughout the study period. Where relevant and necessary, 
interviewers and participants were addressed to maintain confidentiality. 
The interviewers provided clear explanation of the aim/objectives, procedure of the research and 
requirements from the participants, to the participants especially in the local language Isixhosa . 
 
Data collection strictly observed anonymity and therefore there was no disclosure of the participants’ 
identity in the data collection and analysis. The questionnaire did not carry items that require the 
identity of the participants. There was no cost borne by the participants during the course of the study 
 
The participants’ HIV status was not disclosed in any way. The interviewers were recruited from the 
staff of the ARV clinic and a feeder clinic in order to promote and maintain confidentiality of 
information. Participation in the study did not jeopardize the participants’ financial (nil impact on 
grants), physical or social conditions (nil promotion of stigmatization). The administration of the 
questionnaire was done in a private comfortable room within the ARV clinic. 
 
There was no coercion and participation was strictly voluntary. Participants maintain the right to 
withdraw when and if they so wished. Withdrawal by any participant from the study did not in any 
way impact on any aspect of their current management received at the ARV clinic. Thus care received 
at the ARV clinic by the participants was not affected in any way. 
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RESULTS 
 
Gender of HAART non adhering patients 
 
Figure 1: gender (n=215) 
 
 
 
There were 130 (60%) female patients and 85(40%) male patients of the 215 patients that participated in 
the study. (Figure 1) 
 
Ages of HAART non adhering patients 
 
Figure 2: age (n=215) 
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31(14.4%) patients were between the ages of 19-28years, while 68(31.6%) patients were between 29-
38years. 65(30.2%) patients were aged between 39-48years and 41(19.1%) patients were between 49-
58years. 10(4.7%) patients were 59years and above. The mean age of the patients was 40.4years. (Figure 
2) 
 
 
Marital Status of HAART non adhering patients 
 
Figure 3: marital status (n=215) 
 
 
 
Of the 215 patients that participated in the study, 102 (47.4%) were single, 92 (42.8%) were married, 8 
(3.7%) were separated from their marriage, 12 (5.6%) were divorced and 1(0.5%) was cohabiting. (Figure 
3). 
 
Personal Income Source of HAART non adherent patients 
 
Figure 4: income source (n=215) 
  
 
 
 
A total of 48 (22.3%) patients were unemployed on disability grant, 123 (57.2%) patients were 
unemployed and not on disability grant, which is more than half of the total number of participant 
patients, while 44 (20.5%) patients were employed. (Figure 4). 
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Treatment Supporter availability for HAART non adhering patients 
 
Figure 5: treatment supporter (n=215) 
 
 
 
 
More than three-quarters of the patients that participated in the study had treatment supporters. A total of 
185 (86.1%) patients had treatment supporters while 30 (13.9%) patients did not have. (Figure 5) 
 
Duration on HAART by non adhering patients 
 
Figure 6: duration on HAART by non adhering patients (n=215) 
  
 
 
 
A total of 47(21.9%) patients had taken HAART for less than 6 months, 79(36.7%) patients had been on 
HAART between 6-11 months. 81(41.4%) patients had taken HAART for more than 11 months.(Figure 
6) 
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HAART regimen of non adhering patients 
 
Figure 7: HAART regimen of non adhering patients (n=215) 
 
 
 
More than half of the patients, 134 (62.3%) patients, are presently on regimen 1A, 72 (33.5%) patients are 
presently on regimen 1B while 9 (4.2%) patients are on regimen 2.(Figure 7) 
 
Patient related Factors 
 
Figure 8: patient related factors (n=215) 
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(64.7%) patients and 100 (46.5%) patients reported that ‘they were busy with other things’ and ‘the 
weather did not allow them to come to the ARV clinic’ respectively as part of their reasons for defaulting 
HAART. However, only 1(0.5%) patient reported that ‘he uses substances like dagga’, while no patient 
reported to ‘use substances like Methamphetamine (‘tik’). (Figure 8) 
 
Therapy related Factors 
 
Figure 9: therapy related factors (n=215) 
 
 
There were six items in this component. The highest number of patients, 154 (71.6%) patients, reported 
that ‘the pills make them sick’, while the lowest number of patients, 5 (2.3%) patients, reported that they 
‘take herbal medications also’. (Figure 9) 
 
Facility related Factors 
 
Figure 10: facility related factors (n=215) 
 
 
 
There were six items in this component. The highest number of patients, 148 (68.8%) reported that ‘the 
ARV clinic is too far from where they leave’, while no patient (0%) reported that ‘the ARV clinic staff 
are not supportive’ or ‘the ARV clinic staff are unhelpful’. (Figure 10) 
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Down referral 
 
Figure 11: preference to receive HAART at a near-by clinic (n=215) 
 
 
 
 
More than half of the patients, 135 (62.8%) patients, prefer to receive their HAART at a clinic near them, 
while 80 (37.2%) patients did not. (Figure 11) 
 
Figure 12: period for starting HAART at local clinic (n=135) 
 
 
 
Almost all the patients, 130 (96.3%) patients that prefer to take their HAART at a clinic near 
them want this to start within 6 months. 5 (3.7%) patients want to start between 6 and 12 months, 
while no patient want to start after 12 months. (Figure 12) 
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Figure 13: ART handling by ARV clinic (n=215) 
 
 
 
 
More than half of the patients, 137 (63.3%) patients, think that the ARV clinic has enough workers to 
handle the ART roll out, while 78 (36.3%) patients did not think so. (Figure 13) 
 
 
 
 
Figure 14: ART dispensing time at the ARV clinic (n=215) 
 
 
 
More than half of the patients, 120 (55.8%) patients, did not have to wait too long to receive the 
medications at the ARV clinic, while 95 (44.2%) patients did. (Figure 14) 
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DISCUSSION 
 
The aim of the study was to determine the prevalence of established factors affecting HAART adherence 
at the ARV clinic. The study revealed that patient-related factors, therapy-related factors, and facility-
related factors all affect HAART adherence at the clinic though at varying rates. The prevalence rate for 
these factors was 24%. The patient- related factors had a prevalence rate of 12.4% while therapy-related 
and facility-related factors had prevalence rates of 5.8% and 5.7% respectively. This clearly shows that 
patient-related factors affect HAART adherence most at the ARV clinic, and thereby overtly attaching 
more importance to the patient undergoing HAART. 
 
In terms of patient-related factors, the majority of the patients (90.7%) cited that they did not belong to a 
support group and more than half (64.7%) cited that they were busy with other things, as the reasons for 
not taking HAART. The reasons for these responses are due to poor social support structures prevalent in 
the rural districts of the province, as well as preoccupation with social/financial issues like job hunting, 
family funerals and other family engagements. ‘Too busy’ was one of the common reasons for suboptimal 
adherence as reported by Chesney M et al.
31
 Lack of or paucity of social support has  also been shown to 
be associated with lower HAART adherence.
32
 
 
More than two thirds of the patients (71.6%) reported ‘difficulty with dietary restrictions on taking pill’ as 
their main therapy related reason for defaulting HAART. This is in keeping with the main reason cited in 
the study by Nachega JB et al
18
 for HAART default. Another main reason in this section was ‘pills 
making the patients sick’. The HAART regimens presently available in the public sector health system are 
old generation ARVs which in most instances are not without side effects that could be persistent and 
discomforting. The tolerability profile of these ARV’s is very equivocal. Recent ARV’s with improved 
tolerability profiles are still not yet available in the public sector health system due to logistic reasons. 
 
The majority of the patients (68.8%) cited that ‘ the ARV clinic was too far from where they live’ and 
‘there are few staff at the ARV clinic to attend to patients’ as the main facility related reason for 
defaulting HAART. These are in line with the rural nature of the Mount Frere community with poor 
social amenities and paucity of health care workers in rural under-resourced district health care facilities 
all over the country. Some of the reasons for defaulting HAART were under reported by the patients. 
These include; use of substances like cigarette, alcohol, dagga and herbal medications. These habits are 
known to be prevalent in the Mount Frère community. One can attribute these finding to denial on the 
part of the patients due to measurement bias inherent in the interviewer administered questionnaire. 
Utilizing staff from the ARV clinic may have contributed to some bias experienced in this study 
especially the aspect that dealt with the facility-related factors and down referral issues. 
 
Though there are conflicting reports on the predictors of good or poor adherence to HAART, this study 
revealed that female gender, unemployment without disability grant, longer duration on HAART, 
Regimen 1A ARV’s, single marital status, mean age 40.4 years and probably poorly selected unprepared 
treatment supporters, as associations of poor HAART adherence at the ARV clinic. Godin G et al
2
 
reported ‘female sex’ as one of the demographic variables associated with low HAART adherence, which 
is in keeping with this study. The corollary was also the case in the same study using the Generalized 
Estimated Equation (GEE) method where Godin G et al
2
 cited that the male gender was one of the 
predictors of HAART adherence. 
 
A greater percentage of patients (62.8%) prefer to receive their ART at a nearby clinic. This obviously 
would help in saving the cost incurred on transportation to and from the ARV clinic given that poverty is 
rife in this region of the country. Likewise most of the patients also reported that the ‘ARV clinic was too 
far from where they live’. There is a national trend towards empowering the primary healthcare (PHC) 
clinics for ART rollout in order to increase access to HAART. This will mean bringing the services to the 
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communities in line with the principles of primary healthcare. Starting these services within six months 
was overwhelmingly reported by the patients that want to be receiving their HAART at a clinic near them. 
However, the question still remains on whether there is adequate capacity to start and sustain this ART 
rollout at the PHC clinics, bearing in mind that one of the local challenges to ART rollout is under-
developed healthcare infrastructure.
33
 On the other hand, it is very necessary to have more health facilities 
that would deal with manageable patient numbers, instead of having a few large referral health facilities 
which may have difficulty in tracking their patients.
22
 This would ensure continuity of care. 
 
Healthcare workers were thought to be enough to handle the ART rollout at the PHC clinics near the 
patients by more than half (63.3%) of them. This may be far from what is obtainable at these clinics 
which are still grossly under staffed (usually three nurses at each clinic).Approximately an equal number 
of patients reported to either wait too long or not, to receive their medications at the ARV clinic. Several 
factors however affect the turn around time for services rendered at the ARV clinic. These are topics for 
further research especially in the Quality Improvement (QI) audit.  
 
Limitation of the Study 
 
This cross-sectional descriptive study had the usual limitations of the survey methodology. These include 
inability to provide causal/temporal relationships, and the presence of bias (recall, translation, 
interviewer). Patients who were on HAART for <2months were excluded. Due to limited resources and 
time, not all the patients that met the inclusion criteria were included in this study. 
 
Recommendation 
 
More importance should be placed on patient preparation for HAART, and continuous review of patients 
on HAART, especially as their duration on HAART increases, is required. This is due to the fact that 
patient related factors were found to be most prevalent in the study. Efforts should also be made towards 
ensuring that patients to be enrolled on the ART programme are attached to functional support groups. 
Introduction of ARV’s with high tolerability profiles in the public health care sector will aid in decreasing 
the non adherence rate on HAART due to related side effects. Prompt identification and treatment of side 
effects is therefore important in this regard. 
 
There is a compelling need to start the down referral of patients already on HAART at the ARV clinic. 
However, this should be done cautiously so that the benefits would be sustained. This should go hand in 
hand with recruiting more PHC clinic staff and equipping them as well. Finally, the treatment supporter 
selection criteria need to be reviewed. Emphasis should be on the treatment supporters understanding 
their roles and committing towards fulfilling them thereby making them relevant to the ART programme. 
Routine assessment of their impact towards enhancing patients’ adherence to HAART should be done. 
 
Conclusion 
 
The study revealed that the prevalence rate of the factors affecting HAART adherence at the Madzikane 
KaZulu Hospital ARV clinic was 24% amongst HAART non-adhering patients. These patients had the 
prevalence rate of patient-related factors (12.4%) more than double of the prevalence rates of therapy 
related factors (5.8%), and facility related factors (5.7%). Topmost amongst the associated factors for not 
adhering to HAART were: not belonging to a support group, the pills making the patient feel unwell, and 
the ARV clinic being too far from where the patients live. Efforts should be targeted at enrolling the 
patients in support groups, encouraging the use of HAART regimens that have good tolerability profiles, 
and establishing the down referral. 
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Annexure 2 (For participants completing the questionnaires) 
 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
TITLE OF THE RESEARCH PROJECT: 
 
“THE PREVALENCE OF ESTABLISHED FACTORS AFFECTING ADHERENCE TO HIGHLY ACTIVE 
ANTIRETROVIRAL THERAPY (HAART) AT THE ARV CLINIC OF MADZIKANE KAZULU 
MEMORIAL HOSPITAL”. 
 
ETHICS REFERENCE NUMBER: N10/02/034 
 
PRINCIPAL INVESTIGATOR: DR O.O ANIZOBA 
 
ADDRESS: MADZIKANE KAZULU MEMORIAL HOSPITAL MOUNT FRERE EASTERN CAPE 
PROVINCE. 
 
CONTACT NUMBER: 0764891853 
 
You are being invited to take part in a research project. Please take some time to read the information 
presented here, which will explain the details of this project. Please ask the study staff or doctor any 
questions about any part of this project that you do not fully understand. It is very important that you are 
fully satisfied that you clearly understand what this research entails and how you could be involved. Also 
your participation is ENTIRELY VOLUNTARY and you are free to decline to participate. If you say no, 
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this will not affect you negatively in any way whatsoever. You are also free to withdraw from the study at 
any point, even if you do agree to take part. 
 
This study has been approved by the COMMITTEE FOR HUMAN RESEARCH AT STELLENBOSCH 
UNIVERSITY and will be conducted according to the ethical guidelines and principles of the 
international Declaration of Helsinki, South African Guidelines for Good Clinical Practice and the 
Medical Research Council (MRC) Ethical Guidelines for Research. 
 
WHAT IS THE RESEARCH STUDY ALL ABOUT? 
The study will be conducted in Madzikane KaZulu Memorial Hospital ARV Clinic and a total of 263 
patients will be recruited for the study. The study aims to find out the rate at which known factors affect 
the patients adherence to HAART in order to make plans on how to tackle these factors thereby 
improving HAART adherence amongst patients in the ARV Clinic and when the down referral system 
starts. I am embarking on this study because of the concern of the increasing defaulter rate in the ARV 
Clinic and the need to improve adherence at the ARV Clinic presently and in the down referral site later 
on. The study involves getting approval from the Hospital Management and the ARV Clinic, recruiting 
and training interviewers and research assistants, reviewing the ART register and ART Pharmacy records 
to identify patients that defaulted HAART within the period of January 2009 and December 2010, pilot 
testing of the questionnaire and its modification subsequently, data collection by interviewer administered 
questionnaire in English and Isixhosa as appropriate to the identified consenting patients in a private room 
within the ARV Clinic, analyzing the data collected and writing up the study findings.  
 
WHY HAVE YOU BEEN INVITED TO PARTICIPATE? 
You have been invited to participate in this study because this study hopes to find out why you 
experiencing difficulty taking you r medicine/ARVs. This also means that information regarding the 
reason(s) for defaulting HAART will be collected with an interviewer administered questionnaire. This 
questionnaire will be made clear to you and all information obtained will be treated with utmost 
confidence and therefore your identity will not be required in completing the questionnaire. With this 
information we hope to improve the system so that patients on ARV medication can be helped better. The 
completion of this questionnaire will take between 20 and 30 minutes.  
 
WHAT WILL YOUR RESPONSIBILITY BE? 
You will be responsible for completing the questionnaire that will be administered by an interviewer, to 
the best of your honesty and ability.  
 
 
WILL YOU BENEFIT FROM TAKING PART IN THIS RESEARCH? 
There are no personal benefits for taking part in the research but patients at the ARV Clinic presently and 
future patients at the Clinic will benefit from the findings of the research. 
 
ARE THERE RISKS INVOLVED IN YOUR TAKING PART IN THIS RESEARCH? 
There are no known risks involved by participating in this research. However issues of concern to the 
patients may include stigmatization, discontinuation of grants and possible financial costs to be incurred. 
These issues will in no way be affected by taking part in the study. 
 
WHO WILL HAVE ACCESS TO YOUR MEDICAL RECORDS? 
The information obtained will be treated as confidential and protected. When it will be used to write up 
the thesis and published, the identity of the participants will remain anonymous. The Principal 
Investigator and the Research Assistants/Interviewer (who all will be recruited from the ARV Clinic 
Staff) will have access to the information. 
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WILL YOU BE PAID TO TAKE PART IN THIS STUDY AND ARE THERE ANY COSTS 
INVOLVED? 
No you will not be paid to take part in this study and there are no costs involved as you will be 
administered the questionnaire when you will be at the Clinic for your regular monthly Clinic 
appointment though priority will be given to you for the ARV Clinic services on the day you come.  
 
IS THERE ANYTHING ELSE THAT YOU SHOULD KNOW OR DO? 
You can contact Dr O.O Anizoba at tel 0764891853 if you have any further queries or encounter any 
problems. In addition you can contact the Committee for Human Research at 021-9389207 if you have 
any concerns or complaints that have not been adequately addressed by your study doctor. You will 
receive a copy of this information and consent form for your own records. 
 
 
Declaration by Participant 
 
By signing below, I………………………………….agree to take part in a research study entitled THE 
PREVALENCE OF ESTABLISHED FACTORS AFFECTING HAART ADHERENCE AT 
MADZIKANE KAZULU MEMORIAL HOSPITAL ARV CLINIC. 
 
I declare that: 
1. I have read or had read to me this information and consent form and it is written in a language with 
which I am fluent and comfortable. 
 
2. I have had a chance to ask questions and all my questions have been adequately answered. 
 
3. I understand that taking part in this study is VOLUNTARY and I have not been pressurized to take part. 
 
4. I may choose to leave the study at any time and will not be penalized or prejudiced on any way. 
 
5. I may be asked to leave the study before it has finished, if the study doctor or researcher feels it is in 
my best interests, or if I do not follow the study plan, as agreed to. 
 
Signed at(place)………………………on(date)…………………………….2010. 
 
 
…………………………………..                        …………………………………… 
Signature of participant                                        Signature of witness 
 
Declaration by investigator/assistant 
 
I(name)……………………………………………………….declare that: 
 
1. I explained the information in this document to…………………………………… 
 
2. I  encouraged him/her to ask questions and took adequate time to answer them. 
 
3. I am satisfied that he/she adequately understands all aspects of the research, as discussed above. 
 
4. I did/did not use an interpreter. 
 
Signed at(place)…………………..........................on(date)…………………………..2010. 
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……………………………………….                 ……………………………………….. 
Signature of investigator/assistant                        Signature of witness 
 
 
Declaration by interpreter 
 
I(name)………………………………………………declare that: 
 
1. I assisted the investigator(name)……………………………………………..to 
explain the information in this document to( name of 
participant)……………………………………………using the language medium of Isixhosa. 
 
2. We encouraged him/her to ask questions and took adequate time to answer them. 
 
3. I conveyed a factually correct version of what was related to me. 
 
4. I am satisfied that the participant fully understands the content of this informed consent document 
and has all his/her question satisfactorily answered. 
 
Signed at(place)…………………………………..on(date)………………………..2010 
 
 
………………………................              ………………………………………… 
Signature of interpreter                                             Signature of witness. 
 
Annexure 3 (For Focus Group Discussion Participants) 
 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
TITLE OF THE RESEARCH PROJECT: 
 
“THE PREVALENCE OF ESTABLISHED FACTORS AFFECTING ADHERENCE TO HIGHLY ACTIVE 
ANTIRETROVIRAL THERAPY (HAART) AT THE ARV CLINIC OF MADZIKANE KAZULU 
MEMORIAL HOSPITAL”. 
 
ETHICS REFERENCE NUMBER: N10/02/034 
 
PRINCIPAL INVESTIGATOR: DR O.O ANIZOBA 
 
ADDRESS: MADZIKANE KAZULU MEMORIAL HOSPITAL MOUNT FRERE EASTERN CAPE 
PROVINCE. 
 
CONTACT NUMBER: 0764891853 
 
You are being invited to take part in a research project. Please take some time to read the information 
presented here, which will explain the details of this project. Please ask the study staff or doctor any 
questions about any part of this project that you do not fully understand. It is very important that you are 
fully satisfied that you clearly understand what this research entails and how you could be involved. Also 
your participation is ENTIRELY VOLUNTARY and you are free to decline to participate. If you say no, 
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this will not affect you negatively in any way whatsoever. You are also free to withdraw from the study at 
any point, even if you do agree to take part. 
 
This study has been approved by the COMMITTEE FOR HUMAN RESEARCH AT STELLENBOSCH 
UNIVERSITY and will be conducted according to the ethical guidelines and principles of the 
international Declaration of Helsinki, South African Guidelines for Good Clinical Practice and the 
Medical Research Council (MRC) Ethical Guidelines for Research. 
 
WHAT IS THE RESEARCH STUDY ALL ABOUT? 
The study will be conducted in Madzikane KaZulu Memorial Hospital ARV Clinic and a total of 263 
patients will be recruited for the study. The study aims to find out the rate at which known factors affect 
the patients adherence to HAART in order to make plans on how to tackle these factors thereby 
improving HAART adherence amongst patients in the ARV Clinic and when the down referral system 
starts. I am embarking on this study because of the concern of the increasing defaulter rate in the ARV 
Clinic and the need to improve adherence at the ARV Clinic presently and in the down referral site later 
on. The study involves getting approval from the Hospital Management and the ARV Clinic, recruiting 
and training interviewers and research assistants, reviewing the ART register and ART Pharmacy records 
to identify patients that defaulted HAART within the period of January 2009 and December 2010, pilot 
testing of the questionnaire and its modification subsequently, data collection by interviewer administered 
questionnaire in English and Isixhosa as appropriate to the identified consenting patients in a private room 
within the ARV Clinic, analyzing the data collected and writing up the study findings.  
 
WHY HAVE YOU BEEN INVITED TO PARTICIPATE? 
You have been invited to participate in this study because this study hopes to find out why you 
experiencing difficulty taking your medicine/ARVs. This also means that information regarding the 
reason(s) for defaulting HAART will be collected during focus group discussions (FGDs) with an 
interviewer. With this information we hope to improve the system so that patients on ARV medication 
can be helped better. Such focus group discussion (FGD) may last up to about 2 hours and four such 
FGDs may be required.  
 
WHAT WILL YOUR RESPONSIBILITY BE? 
During these focus group discussion sessions (FGD), you will be required to discuss the reasons for not 
taking your medication with other similarly affected patients in a focus group discussion. 
 
 
WILL YOU BENEFIT FROM TAKING PART IN THIS RESEARCH? 
There are no personal benefits for taking part in the research but patients at the ARV Clinic presently and 
future patients at the Clinic will benefit from the findings of the research. 
 
ARE THERE RISKS INVOLVED IN YOUR TAKING PART IN THIS RESEARCH? 
There are no known risks involved by participating in this research. However issues of concern to the 
patients may include stigmatization, discontinuation of grants and possible financial costs to be incurred. 
These issues will in no way be affected by taking part in the study. 
 
WHO WILL HAVE ACCESS TO YOUR MEDICAL RECORDS? 
The information obtained will be treated as confidential and protected. When it will be used to write up 
the thesis and published, the identity of the participants will remain anonymous. The Principal 
Investigator and the Research Assistants/Interviewer (who all will be recruited from the ARV Clinic 
Staff) will have access to the information. 
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WILL YOU BE PAID TO TAKE PART IN THIS STUDY AND ARE THERE ANY COSTS 
INVOLVED? 
No you will not be paid to take part in this study and there are no costs involved as the focus group 
discussions will be arranged to coincide with the days when you will be attending the Clinic for your 
regular monthly appointments and may involve 4 such sessions. 
 
IS THERE ANYTHING ELSE THAT YOU SHOULD KNOW OR DO? 
You can contact Dr O.O Anizoba at tel 0764891853 if you have any further queries or encounter any 
problems.  In addition you can contact the Committee for Human Research at 021-9389207 if you have 
any concerns or complaints that have not been adequately addressed by your study doctor. 
You will receive a copy of this information and consent form for your own records. 
 
 
 
 
Declaration by Participant 
 
By signing below, I………………………………….agree to take part in a research study entitled THE 
PREVALENCE OF ESTABLISHED FACTORS AFFECTING HAART ADHERENCE AT 
MADZIKANE KAZULU MEMORIAL HOSPITAL ARV CLINIC. 
 
I declare that: 
1. I have read or had read to me this information and consent form and it is written in a language with 
which I am fluent and comfortable. 
 
2. I have had a chance to ask questions and all my questions have been adequately answered. 
 
3. I understand that taking part in this study is VOLUNTARY and I have not been pressurized to take part. 
4. I may choose to leave the study at any time and will not be penalized or prejudiced on any way. 
 
5. I may be asked to leave the study before it has finished, if the study doctor or researcher feels it is in 
my best interests, or if I do not follow the study plan, as agreed to. 
 
Signed at(place)………………………on(date)…………………………….2010. 
 
 
…………………………………..                        …………………………………… 
Signature of participant                                        Signature of witness 
 
Declaration by investigator/assistant 
 
I(name)……………………………………………………….declare that: 
 
5. I explained the information in this document to…………………………………… 
 
6. I  encouraged him/her to ask questions and took adequate time to answer them. 
 
7. I am satisfied that he/she adequately understands all aspects of the research, as discussed above. 
 
8. I did/did not use an interpreter. 
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Signed at(place)…………………..........................on(date)…………………………..2010. 
 
 
 
……………………………………….                 ……………………………………….. 
Signature of investigator/assistant                        Signature of witness 
 
 
Declaration by interpreter 
 
I(name)………………………………………………declare that: 
 
5. I assisted the investigator(name)……………………………………………..to 
explain the information in this document to( name of 
participant)……………………………………………using the language medium of Isixhosa. 
 
6. We encouraged him/her to ask questions and took adequate time to answer them. 
 
7. I conveyed a factually correct version of what was related to me. 
 
8. I am satisfied that the participant fully understands the content of this informed consent document 
and has all his/her question satisfactorily answered. 
 
Signed at(place)…………………………………..on(date)………………………..2010 
 
 
………………………................              ………………………………………… 
Signature of interpreter                                             Signature of witness. 
Annexure 4 (Information letter) 
 
1
st
 December 2009. 
 
 
Madzikane KaZulu Memorial Hospital 
Mount Frere. 
 
 
Dear Participant, 
 
I am Dr Anizoba, a third year student, in the Division of Family Medicine and Primary Care, Faculty of 
Health Sciences, University of Stellenbosch. I am also working as a medical officer at Madzikane kaZulu 
Memorial Hospital in Mount Frere. 
 
I herewith kindly request that you assist with the completion of the questionnaire that will be 
administered to you by the research assistants. We are in the process of conducting research to establish 
the frequency of known factors that affect antiretroviral therapy adherence at the ARV clinic of the 
hospital. This research is conducted as part of my academic requirement in the MMed (Family Medicine) 
degree. 
 
Please be assured that your participation in this study WILL NOT adversely affect your care at the ARV 
clinic in any way. Confidentiality will be strictly maintained throughout the study period, and there will 
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be no disclosure of personal information in any form whatsoever. You are also free at any time to quit 
participating in the research at your own discretion. Kindly feel free to get clarifications from me or the 
research assistants concerning any issues within the study or any queries you may still have.  
 
Thank you for your much valued time and assistance in this regard. 
 
Yours sincerely 
 
 
___________ 
Dr Anizoba 
 
Medical Officer 
Madzikane KaZulu Memorial Hospital 
Mount Frere. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Annexure 5 (Permission letter) 
 
1
st
 December 2009. 
 
The Chief Executive Officer, 
Madzikane KaZulu Memorial Hospital 
Mount Frere. 
 
Dear Sir 
 
Permission to conduct a research 
 
I hereby apply for permission to conduct research at the ARV clinic of the hospital. I am presently a part-
time 3
rd
 year student in the Division of Family Medicine and Primary Care, Faculty of Health Sciences, 
University of Stellenbosch. 
 
As part of the degree, I am required to conduct research which I have decided to do in the ARV clinic in 
order to assist in improving on the quality of service rendered there. The research title is: “The prevalence 
of established factors affecting HAART adherence at the ARV clinic of Madzikane KaZulu Memorial 
Hospital”. This research will assist in the overall quality of care rendered to our existing pool of patient 
attending the ARV clinic. In particular it is hoped that the research will help decrease the HAART default 
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rate of patients attending the ARV clinic, and also contribute towards kick-starting the down referral 
system. 
 
The required research funding has been applied for and this research will not pose any harm to the 
patients in the ARV clinic or the hospital at large, and confidentiality will be strictly maintained 
throughout the study. A copy of the research proposal is available for your perusal. 
 
I look forward to receiving permission to proceed with this research project. 
 
Yours Sincerely 
 
 
_______________ 
Dr O.O Anizoba. 
 
Medical Officer 
Madzikane KaZulu Memorial Hospital 
Mount Frere. 
Eastern Cape 
 
 
 
 
 
 
 
 
 
 
 
Annexure 6   
 
QUESTIONNAIRE (interviewer-administered) 
 
Instruction: Kindly complete this questionnaire completely and accurately by circling the items best 
applicable to the questions/statements. Place a tick (√) in the box as applicable in the demographics 
section. 
 
DEMOGRAPHICS 
1. Gender 
a. male…………….. 
b. female…………... 
2. Age(years) 
a. 19-28………………….. 
b. 29-38……… ………… 
c. 39-48……………….… 
d. 49-58……………….… 
e. ≥59…………………… 
 
3. Marital Status 
a. Married…….….. 
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b. Single…………. 
c. Separated……… 
d. Divorced………. 
e. Cohabiting…….. 
 
4. Income Source 
a. Employed………………….. 
b. Unemployed on DG……….. 
c. Unemployed not on DG…… 
 
5. Treatment Supporter 
a .Yes………………….... 
b. No……………………. 
 
6. Length of time on HAART(months) 
a.<6…………………….``. 
b.6-11……………………` 
c.>11…………………….. 
   
7. HAART Regimen presently on 
a.1A……………….. 
b.1B……………….. 
c.2………………… 
d. Non standard…… 
 
Please answer the following TRUE or FALSE questions 
 
 
 
 
PATIENT RELATED FACTORS 
 
1. I am often away from home and cannot take my medication 
…            True                                           False              
2. I was busy with other things and could not take the medication 
        …     True                                           False                         
3. I simply forgot to take my medication 
           True                                           False              
4. I was sick or ill during the time that I needed to take my medication 
                 True                                           False              
5. I did not want others to notice me taking medications 
                 True                                           False               
6. I had a change in my daily routine 
                 True                                           False              
7. I did not have money for transport to the ARV clinic 
                 True                                           False               
8. The weather did not allow me to come to the ARV clinic (rainy/very cold) 
                 True                                           False             
9. I have no one to remind me 
                 True                                           False                                 
10. I do not belong to a support group 
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                 True                                           False              
11. I use substances like cigarette  
                 True                                           False              
12. I use substances like alcohol 
                 True                                           False                                              
13. I use substances like dagga  
                 True                                           False             .   
14 I use substances like Tik 
                 True                                           False              
 
 
THERAPY RELATED FACTORS 
 
1. I find that I have too many pills to take 
                True                                           False              
2. I wanted to avoid side effects 
                True                                           False                 . 
3. I found it difficult to take pills at specified times 
               True                                           False              
4. I have difficulty with dietary restrictions on my pills 
               True                                           False              
5. The pills make me sick (e.g. nausea/vomiting/rash/headache etc) 
                True                                           False                        
6. I take herbal medications also 
                True                                           False              
 
 
 
 
 
FACILITY RELATED FACTORS 
 
1. The ARV clinic is too far from where I live 
                True                                           False              
2. The medications were out of stock at the ARV clinic  
                True                                           False              
3. The ARV clinic staff are not supportive 
                True                                           False              
4. The ARV clinic staff are unfriendly 
                True                                           False              
5. The ARV clinic staff are unhelpful 
                True                                           False              
6. There are few staff at the ARV clinic to attend to patients 
                True                                           False                    
 
DOWN REFERRAL  
 
1. Do you prefer to receive your ART at a clinic near you?  
 YES                                                        NO 
 
2. If yes, when do you want to start taking your ART at a clinic near you?  
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       WITHIN 6 MONTHS  ,  6-12 MONTHS ,   AFTER 12 MONTHS 
 
3. Do you think that the clinic has enough workers to handle the ART roll out?  
       YES                                                        NO. 
 
4.  Do you find that you have to wait too long to receive your medication? 
YES                                                        NO. 
 
 
……….. 
 
Key:  HAART----------Highly Active Antiretroviral Therapy 
           DG-----------------Disability Grant 
          ART---------------Anti-retroviral Therapy 
 
        
 
NB: This questionnaire was adapted from the AACTG
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( Adult AIDS Clinical Trials Group) adherence 
instrument which is standardized, with modifications to suit the study setting. 
 
 
 
 
 
 
 
 
 
 
 
Annexure 7 
 
Questions for Focus Group Discussion 
 
1. The ARV clinic started initiating people on HAART in 2007, what can you say about the 
performance of the clinic from then till now? (objective: service comparison over time) 
 
2. Many people are now on HAART at the ARV clinic, what makes you motivated to continue 
taking the medication? (objective: motivation for taking HAART) 
 
 
3. Think about the period from January 2009 to December 2010, how often do you think you 
missed taking your medications? 
(objective: treatment default frequency over the study period) 
 
4. People often have different reasons for doing things, what reasons do you have for missing your 
medications between January 2009 and December 2010?   
     (objective: reasons for treatment default over the study   
      period) 
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5. There are a number of ways of addressing any issue, what do you think could assist you not to 
miss your medications? (objective: solutions to treatment default) 
 
6. Finally, would you prefer taking your HAART at a clinic nearer to you? (objective: opinion on 
down referral) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Annexure 8 
HEALTH RESEARCH ETHICS COMMITTEES 
Faculty of Health Sciences, Stellenbosch University 
CHECKLIST-GENERAL 
To be completed by Applicant and checked by Ethics Admin Office 
 
PROTOCOL TITLE:THE PREVALENCE OF ESTABLISHED FACTORS AFFECTING ADHERENCE TO 
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY(HAART) AT MADZIKANE KAZULU MEMORIAL 
HOSPITALS’  ARV CLINIC 
 
PROTOCOL 
NUMBER 
 PROTOCOL 
VERSION 
 PROTOCOL 
DATE 
June 06th 
2010 
      
 
 CV (max 2 pages) Investigator 
Declaration  
Conflict of 
Interest 
statement 
signed. 
Admin 
Office 
Comments 
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PRINCIPAL 
INVESTIGATOR:  
Dr Anizoba O.O 
Yes Yes Yes  
SUB-INVESTIGATORS     
1.      
2.      
3.      
4.      
5.      
6.      
OTHER STAFF     
     
     
 
 Applicant Comments Admin Office 
 Y /N / NA   
Applicant Signature Y   
Supervisor Signature Y   
HODiv Signature Y   
Protocol synopsis Y   
Full protocol Y   
Page numbers on 
protocol? 
Y   
Budget Y   
Informed Consent 
Form                              
Y   
Questionnaires Y   
Other measuring 
tools/instruments. 
Y   
Recruitment  
material/ 
Advertisement(s) 
NA   
DoH or other letters 
of approval to 
conduct research 
Y   
Material Transfer 
Agreement 
NA   
A. Section B:  To Be completed by Applicant  
 
INFORMED CONSENT FOR RESEARCH CHECKLIST. 
Element Yes 
(PI) 
Yes/No 
(Reviewer) 
1. That consent is being sought from the participant to 
participate in research. 
Yes  
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2. The purpose of the research and where it will be 
conducted. 
Yes  
3. The expected duration of the participant’s 
involvement in the research. 
Yes  
4. The total number of participants that will be involved  
at this site and/or South Africa and worldwide. 
Yes  
5. A description of all the processes and procedures to 
which the participant will be subjected, emphasising 
any experimental procedures that are innovative 
and have not been used in medical practice. 
Yes  
6. The principal investigator’s name and contact 
details. 
Yes  
7. Explanation of participants responsibilities. Yes  
8. Explanation of any randomization process if 
applicable). 
Yes  
9. Circumstances that may result in the project being 
terminated or the participant being withdrawn. 
Yes  
10. A description of foreseeable risks and discomforts. Yes  
11. A description of benefits to the participant or others 
both during and after the research. If there are no 
expected benefits, the participant must specifically 
be made aware of this. 
Yes  
12. Disclosure of alternative procedures and course of 
treatments available if applicable 
NA  
13. Description of extent to which confidentiality will be 
maintained and protected. 
Yes  
14. Statement that sponsors of the study, study monitors 
or auditors or REC members may need to inspect 
research records. 
NA  
15. Statement that the Health Research Ethics 
Committee has approved the research. 
YES  
16. Contact details of the committee. NA  
17. Explanation of how research related injury will be 
managed and details of insurance if applicable.  
NA  
18. Explanation as to whom to contact in the event of 
research related injury. 
NA  
19. Participation in the study is entirely voluntary Yes  
20. Participants are free to withdraw at any point 
without explanation or any negative consequences. 
Their routine health care will not be adversely 
affected. 
Yes  
21. Participants must be informed of their rights to be 
told any new relevant information that arises during 
the course of the trial and the ICF should be revised, 
where appropriate to incorporate this information.  
NA  
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22. That the study will be conducted according to the 
International Declaration of Helsinki and other 
applicable international ethical codes for research 
on human subject. 
Yes  
23. Any expense to which the participant may be liable. No  
24. Explanation regarding payment for participation or 
out of pocket expenses 
NA  
25. Identity of the funder , where applicable and any 
potential conflict of interests. 
NA  
26. Where appropriate, the participant should also be 
requested/advised to inform his general practitioner 
and  life insurance company or  medical aid of 
his/her participation. 
                  Not considered appropriate/necessary 
NA  
27. Simple, clear language has been used ( Maximum 
Grade 8 reading level) and all medical and 
technical terms have been explained. 
Yes  
  
 Section C. To be completed by Applicant 
 Yes 
(PI) 
Yes/No 
(Reviewer) 
1. Does the study have relevance and scientific or 
clinical value and applicability to the proposed 
research population? 
Yes  
2. Does the protocol include an adequate literature 
review? 
Yes  
3. Is the selection of subjects equitable and 
appropriate; adequate consideration and 
protection of vulnerable research populations. 
Yes  
Annexure 9 
SYNOPSIS / SUMMARY OF RESEARCH PROPOSAL 
Student: Dr OO Anizoba; Supervisor: Dr Michael Pather 
PROJECT TITLE 
The prevalence of established factors affecting  Highly Active Antiretroviral Therapy(HAART) adherence 
at the Madzikane KaZulu Memorial Hospitals’ ARV clinic. 
Introduction: 
The problem inspiring the research stems from the context of an increasing defaulter rate, increasing 
number of clients on HAART, and increasing number of clients awaiting initiation on HAART. With the 
same number of ARV staff over the years, and the down referral system yet to commence, the work load 
in the ARV clinic and treatment defaulting rate will tend towards increasing. The researcher was 
motivated and committed to doing this research because of the need to improve adherence, and ultimately 
decrease treatment defaulting rate at the ARV clinic, and also contribute towards the down referral system 
which is long over due. 
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With the increasing number of people infected with HIV everyday and the need to increase access to 
HAART, adherence issues will always be very crucial for any successful HAART programme. Adherence 
has been defined severally in terms of clinic attendance, deficit between number of pills given and 
number of pills consumed and obeying dietary restrictions with respect to therapy. However, there is still 
no single perfect tool used in measuring adherence. Therapy related factors, patients related factors and 
facility related factors have been widely reported to affect adherence to HAART. 
 
Research Question; 
What is the prevalence of established factors affecting adherence to HAART at the Madzikane KaZulu 
Memorial Hospitals’ ARV clinic?  
 Aim 
The research aim is to determine the prevalence of established factors affecting adherence to HAART at 
the Madzikane KaZulu Memorial Hospitals’ ARV clinic.  
 
Objectives 
The objectives of the research include;  
 
1.To conduct an audit on case files of patients on HAART over the study period. 
2.To explore the behavioural aspects of poor HAART adherence in a focused group discussion. 
3. To determine the predictors of good HAART adherence. 
 
 
Methods 
Setting of the study is in an ARV clinic in Madzikane KaZulu Memorial Hospital, a district hospital in 
the Mount Frere Community of the Alfred Nzo District which is predominantly rural, in the Eastern Cape 
Province .The hospital is a modern district hospital which was under the hospital revitalization 
programme. Its a 269 bed hospital, with 223 usable beds which became functional in September 2006, 
and is located in Mount Frere, along the N2 national road. It serves the Mount Frere community as well as 
part of the Mount Ayliff and Tabankulu communities. The ARV clinic has four feeder clinics, ten staff 
members and over one thousand clients. The ARV clinic started initiating clients on HAART since March 
2007, and is affiliated to the Infectious Diseases Clinic of Umtata General Hospital. 
Study design 
The study is a cross sectional descriptive study. An audit of case files of patients on HAART between 
January 2009 and December 2010, will be done to identify the treatment defaulters. After this, a focused 
group discussions will be done with 12 randomly selected treatment defaulters.. The findings from the 
FGDs will be incorporated into the data collection tool (questionnaire). 
Piloting 
The questionnaire will be piloted on a randomly selected 15 treatment defaulting patients, and the 
researchers colleagues (for inputs/modifications) after which the final version of the questionnaire will be 
administered to the selected patients by trained interviewers/field workers. 
Inclusion and exclusion criteria 
The inclusion criteria are; adult patients who are 19 years and above, who have been on HAART for at 
least 2 months within January 2009 and December 2010. Exclusion criteria are; patients with cognitive 
impairment and transfer-out patients to other facilities.  
Sample 
A total of 263 patients will be used as the sample size from a sample frame of 1014 patients on HAART 
at the ARV clinic, with a confidence interval of 95% and precision of 6%. The anticipated benefits 
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include; provision of information on the adherence patterns in a deeply rural setting of Madzikane KaZulu 
Memorial Hospitals’ ARV clinic, promoting adherence enhancing structures already at the clinic thereby 
decreasing treatment default rate, and contributing towards kick-starting the down referral system. 
Ethical considerations (See main proposal) 
Ethical considerations include; written informed consent is to be obtained from each participant prior to 
taking part in the research, strict maintenance of confidentiality throughout the research, non disclosure of 
participants HIV status/identity, interviewer administered questionnaire to be done in a private 
comfortable room within the ARV clinic, and participation will be strictly on voluntary basis and 
participants can withdraw at any time they wish to. 
Time frame (See table I main proposal) 
The estimated duration for the research is 5 months possibly from March to August 2010 depending on 
the time of approval from the research ethics committee and other logistics mentioned in the research 
protocol. 
Budget (See table II main proposal) 
The research budget was estimated to be R8000 which includes indirect cost of about R1700. The major 
part of the research will be from personal funds and from funds applied for from the MRC. 
 
 
